Unique ID issued by UMIN | UMIN000015087 |
---|---|
Receipt number | R000017547 |
Scientific Title | A randomized and comparative study of DPP4 inhibitors versus SGLT2 inhibitors using cotinuous glucose monitoring (CGM) |
Date of disclosure of the study information | 2014/09/08 |
Last modified on | 2017/03/27 17:31:34 |
A randomized and comparative study of DPP4 inhibitors versus SGLT2 inhibitors using cotinuous glucose monitoring (CGM)
A randomized and comparative study of DPP4 inhibitors versus SGLT2 inhibitors using cotinuous glucose monitoring (CGM)
A randomized and comparative study of DPP4 inhibitors versus SGLT2 inhibitors using cotinuous glucose monitoring (CGM)
A randomized and comparative study of DPP4 inhibitors versus SGLT2 inhibitors using cotinuous glucose monitoring (CGM)
Japan |
Type 2 diabetes mellitus
Endocrinology and Metabolism |
Others
NO
The purpose of this study is to investigate the effect of SGLT2 inhibitors or DPP4 inhibitors on glycemic control and safty in patients with type 2 diabetes.
Safety,Efficacy
Exploratory
Pragmatic
SD of blood glucose by CGM
1)averate blood glucose, MAGE by CGM
2)FPG and PPG at 1, 2, 3, 4, 5, 6, 7 days of treatment
3)%chagne of FPG, HbA1c,IRI,CPR, a from baseline
4)a questionnaire survey
Interventional
Parallel
Randomized
Open -no one is blinded
Active
NO
YES
Institution is considered as adjustment factor in dynamic allocation.
NO
Central registration
2
Treatment
Medicine |
SGLT2 inhibitors:
This study to examine the change in SD of 24h and MAGE by CGM,blood glucose levels,Body weight,urine volume before and after the start.
DPP-4 inhibitors:
This study to examine the change in SD of 24h and MAGE by CGM,blood glucose levels,Body weight,urine volume before and after the start.
20 | years-old | <= |
85 | years-old | > |
Male and Female
1)before test registration - the meal and exercise cure for one month or more or a meal and an exercise cure, and diabetic medicine and inpatient
2)HbA1c(NGSP):more than 7.0%, less than 14.0%
3)126mg/dl<=FPG<250mg/dl and 200mg/dl<=PPG<350mg/dl
4)eGFR more than 45ml/min/1.73m 2
5)Type 2 diabetes
6)Pts with written IC
7)Age more than 20, less than 85
1)severe ketosis, diabetic coma within 6 months
2)severe infection, before operation, severe trauma
3)severe hepatic dysfunction
4)or severe renal dysfunction (Cr: more than 1.5mg/dl)
5)Patients who use of insulin
6)pregnacy
7)Allergy for sitagliptin, nateglinide,liraglutide and exenatide
8)Patients judged by the investigator to be ineligible for some other reason
20
1st name | |
Middle name | |
Last name | Tadashi Yamakawa |
Yokohama City University Medical Center
Department of Endocrinology and Diabetes
4-57 Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan
045-261-5656
naibunpi@urahp.yokohama-cu.ac.jp
1st name | |
Middle name | |
Last name | Joe Nagakura |
Yokohama City University Medical Center
Department of Endocrinology and Diabetes
4-57 Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan
045-261-5656
jo0806nagakura@hotmail.com
Yokohama City University Medical Center
None
Self funding
JAPAN
NO
横浜市立大学附属市民総合医療センター(神奈川県)
横須賀市立市民病院(神奈川県)
2014 | Year | 09 | Month | 08 | Day |
Published
https://www.jstage.jst.go.jp/article/endocrj/63/3/63_EJ15-0500/_article
Completed
2014 | Year | 09 | Month | 08 | Day |
2014 | Year | 09 | Month | 08 | Day |
2016 | Year | 02 | Month | 01 | Day |
2016 | Year | 02 | Month | 01 | Day |
2016 | Year | 03 | Month | 01 | Day |
2016 | Year | 03 | Month | 02 | Day |
2014 | Year | 09 | Month | 08 | Day |
2017 | Year | 03 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017547